Neumora Therapeutics is no longer the late-stage depression story the public listing was built around. In mid-June the company halted navacaprant after two additional pivotal studies in major depressive disorder failed to separate from placebo on the primary mood scale. That completed a shutout across the late-stage program. The miss forced a 35 percent staff cut. What remains is a smaller Watertown operator with three earlier programs, a venture term loan, and an explicit going concern warning that sits next to a management claim of cash into the third quarter of next year. The investment debate is whether the leftover pipeline is a genuine second act or a cash-box option the market is already marking toward a distressed stub.
Cash at mid-year was $117 million. That balance is down from $183 million at year-end. First-half operating cash use ran near $86 million. The second-quarter net loss narrowed to $43 million as research spending fell after the depression program ended. The equity now capitalizes the company at roughly $137 million, which is only a modest premium to net cash after the K2 HealthVentures term loan. The residual enterprise value is therefore a thin option on whatever the remaining programs can still prove.
The next several months resolve whether the Alzheimer's agitation signal holds at higher doses, whether the muscarinic schizophrenia program produces a usable early clinical profile, and whether the at-the-market equity facility can refill the cash account without breaking the Nasdaq bid-price floor again. Management also named Joshua Pinto chief executive in August, moving founder Paul Berns to executive chair. The question is whether that reset buys enough time for a mid-stage signal, or whether the going concern language is the more honest map of the next year.